[DUSA LOGO]

INNOVATION IN PHOTODYNAMIC THERAPY



DUSA PHARMACEUTICALS, INC.

FOR IMMEDIATE RELEASE



                    DUSA PHARMACEUTICALS REVIEWS AND UPDATES

                           PROGRESS AT ANNUAL MEETING



WILMINGTON, MA. JUNE 15, 2000 - DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA)

held its Annual Meeting today at the Company's new Wilmington, Mass.

headquarters. Dr. Geoffrey Shulman, President and CEO, and the rest of the

management team, reviewed the accomplishments of the past year, and updated

shareholders on the outlook for the remainder of this year.



Dr. Shulman stated "1999 was a year of tremendous achievement for DUSA. In

December, following a multi-year clinical trial development program, the Company

received FDA approval for the Levulan(R) (aminolevulinic acid HCl, ALA)

Kerastick(TM) 20% topical solution Photodynamic Therapy (PDT). The treatment is

indicated for non-hyperkeratotic Actinic Keratoses (AKs) of the face and scalp.

The clinical trial version of the BLU-U(TM) brand light source was also

approved."



"The other key milestone for '99 was the signing in November of a worldwide

dermatology marketing, development and supply agreement with Schering AG of

Germany, to market Levulan(R) PDT for dermatology indications, and to jointly

develop additional indications. With Schering AG's strong commitment to

dermatology, and excellent worldwide marketing capabilities, DUSA feels that

Schering AG is an ideal dermatology partner. The financial terms reflected the

late stage of Levulan(R) PDT development, with DUSA due to receive a total of

$30 million in upfront and launch-related payments, a significant share of

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC